Abstract: The invention provides for polypeptides that bind to Ras proteins and methods of using the same, as described herein. For example, the disclosure provides an isolated polypeptide comprising a fibronectin domain, and a first peptide domain at least 90% identical to an amino acid sequence selected from a group consisting of (SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10), and a second peptide domain at least 90% identical to an amino acid sequence selected from a group consisting of (SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15) that specifically binds to an activated Ras protein.

Abstract: Methods useful for preventing, limiting, or treating ischemia reperfusion injury in a mammal are disclosed. More particularly, this invention relates to administering A2b adenosine receptor antagonists to prevent, limit or treat ischemia reperfusion injury.

Abstract: Methods and pharmaceutical compositions of matter are disclosed and claimed relating to cardioprotective effect mediated by delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptor agonists. Further, methods drawn to reducing ischemic damage to organs and tissues having delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptors are disclosed and claimed. Specifically, methods and pharmaceutical compositions of matter are taught as a means of providing cardioprotective treatment through the administration of delta (.delta.) opioid receptor agonists or more specifically delta-1 (.delta..sub.1)-opioid receptor agonists, such as TAN67(-). Said methods and pharmaceutical compositions are envisioned as a means of reducing myocardial infarction arising from the onset and sequelae of myocardial ischemia.